Considering that CD5 is another inhibitory receptor involved in the negative modulation of the TCR signaling, as well as its high structural and functional homology with CD6 (28), CD5 expression on isotype control or itolizumab-treated T cells challenged with tumor cell lines was evaluated. Here, CD5 is linked to neoplasm.